TGTGInsighttelegram intelligenceLIVE / telegram public index
← GitHub Trends

TGINSIGHT SIMILAR POSTS

Find similar content

Source channel @githubtrending · Post #14693 · May 10

#jupyter_notebook#a2a#agentic_ai#dapr#dapr_pub_sub#dapr_service_invocation#dapr_sidecar#dapr_workflow#docker#kafka#kubernetes#langmem#mcp#openai#openai_agents_sdk#openai_api#postgresql_database#rabbitmq#rancher_desktop#redis#serverless_containers The Dapr Agentic Cloud Ascent (DACA) design pattern helps you build powerful, scalable AI systems that can handle millions of AI agents working together without crashing. It uses Dapr technology with Kubernetes to efficiently manage many AI agents as lightweight virtual actors, ensuring fast response, reliability, and easy scaling. You can start small using free or low-cost cloud tools and grow to planet-scale systems. The OpenAI Agents SDK is recommended for beginners because it is simple, flexible, and gives you good control to develop AI agents quickly. This approach saves costs, avoids vendor lock-in, and supports resilient, event-driven AI workflows, making it ideal for developers aiming to create advanced, cloud-native AI applications[1][2][3][4]. https://github.com/panaversity/learn-agentic-ai

Results

2 similar posts found

Search: #drugdevelopment

当前筛选 #drugdevelopment清除筛选
Crypto M - Crypto News

@CryptoM · Post #64470 · 04/09/2026, 01:45 AM

🚀 Hong Kong's Innovative Drug Sector Gains Momentum Hong Kong's innovative drug sector is experiencing a surge, with several companies showing significant gains. According to Jin10, Ascletis Pharma (01672.HK) saw an increase of over 3%, while Hansoh Pharmaceutical (03692.HK) rose by more than 2%. Other companies such as WuXi AppTec (02359.HK) and Sihuan Pharmaceutical (00460.HK) also followed suit with upward trends. #HongKong#Pharmaceuticals#Biotech#Innovation#StockMarket#Healthcare#DrugDevelopment

Venture Village Wall 🦄

@venturevillagewall · Post #3642 · 12/21/2024, 10:23 AM

PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment